Table 3.
Clinicopathological features of the enrolled studies with high expressed PODXL in patients with cancer
| Clinicopathological parameters | Studies | No. of patients | Risk of high PODXL OR (95% CI) |
Significant Z |
P-value | Heterogeneity I2 (%) |
P-value | Model |
|---|---|---|---|---|---|---|---|---|
| Age (< 65 vs ≥ 65) | 10 | 2905 | 0.88 (0.71, 1.10) | 1.11 | 0.269 | 42.6 | 0.084 | Fixed effects |
| Gender (male vs female) | 11 | 3081 | 1.04 (0.82, 1.32) | 0.32 | 0.749 | 0 | 0.835 | Fixed effects |
| Tumor size (< 5 cm vs ≥5 cm) | 5 | 1334 | 0.90 (0.61, 1.34) | 0.50 | 0.614 | 0 | 0.703 | Fixed effects |
| TNM stage (III-IV vs I-II) | 12 | 2417 | 1.63 (1.19, 2.23) | 3.04 | 0.002 | 13.1 | 0.319 | Fixed effects |
| Tumor grade (3–4 vs 1–2) | 6 | 2268 | 4.29 (1.84, 9.99) | 3.38 | 0.001 | 78.6 | 0 | Random effects |
|
Tumor differentiation (moderate/well vs poor) |
6 | 1429 | 2.84 (1.82, 4.42) | 4.62 | 0 | 0 | 0.559 | Fixed effects |
|
Distant metastasis (positive vs Negative) |
3 | 475 | 5.46 (2.55, 11.66) | 4.38 | 0 | 44.5 | 0.165 | Fixed effects |
|
Lymph node metastasis (positive vs negative) |
6 | 1574 | 1.51 (1.03, 2.22) | 2.11 | 0.034 | 0 | 0.614 | Fixed effects |
|
Neural invasion (positive vs negative) |
3 | 264 | 2.43 (1.02, 5.79) | 2.00 | 0.045 | 0 | 1.000 | Fixed effects |
|
Vascular invasion (positive or negative) |
6 | 1240 | 2.27 (1.56, 3.30) | 4.29 | 0 | 2.1 | 0.403 | Fixed effects |